G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of Trilaciclib

G1 Therapeutics, Inc. and Boehringer Ingelheim announced that COSELA™(trilaciclib) for injection is now available in the U.S. 

On February 12, 2021, the U.S. Food and Drug Administration (FDA) approved COSELA to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

It is the first and only therapy designed to help protect bone marrow (myeloprotection) when administered prior to treatment with chemotherapy.

Read press release.

Posted on 3/10/2021